NCT02998671已完成2 期
A Randomized, Subject and Investigator Blinded, Placebo-controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 11
- 主要终点
- Total Inflammatory Facial Lesion Count at Day 85
研究概览
简要总结
The study was designed primarily to assess preliminary efficacy and safety of CJM112 in patients with moderate to severe inflammatory acne and to determine if CJM112 has an adequate clinical profile for further clinical development. In addition, sustainability of response and dose relationship were to be explored.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects aged 18 to 45 years of age included, and otherwise in good health as determined by medical history, physical examination, vital signs, ECGs and laboratory tests at screening.
- •Body weight between 50 and 120 kg, inclusive at screening.
- •Patients with papulo-pustular acne vulgaris with between 25 and 100 facial inflammatory lesions (papules, pustules and nodules), and presence of non-inflammatory lesions (open and closed comedones) in the face at screening and baseline, who have failed systemic therapy for inflammatory acne.
- •No more than 5 facial inflammatory nodules at screening and baseline.
- •Investigator's Global assessment (IGA) score of at least moderate (3) acne severity on the face at screening and baseline.
排除标准
- •Appropriate wash out periods are required for investigational drugs, any oral/systemic treatment for acne, systemic or lesional injected (for acne) corticosteroids or systemic immunomodulators, any systemic hormonal treatments, previous treatment with biologics, oral retinoids (in particular isotretinoin) and any topical anti-acne treatment.
- •Use of facial medium depth chemical peels (excluding home regimens) within 3 months prior to baseline.
- •Any live vaccines (this includes nasal-spray flu vaccine) starting from 6 weeks before baseline.
- •Any other forms of acne
- •Any severe, progressive or uncontrolled medical or psychiatric condition or other factors at randomization that in the judgment of the investigator prevents the patient from participating in the study.
- •History of hypersensitivity or allergy to the investigational compound/compound class being used in this study.
- •Active systemic infections (other than common cold) during the 2 weeks prior to baseline.
- •History of severe systemic Candida infections or evidence of Candidiasis in the 2 weeks prior to baseline.
- •Evidence of active tuberculosis at screening. All patients will be tested for tuberculosis status using a blood test (QuantiFERON®-TB (Tuberculosis) Gold In-Tube). Patients with evidence of tuberculosis may enter the trial afteradequate treatment has been started according to local regulations.
- •Patients with known active Crohn's disease
- •History of immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test result at screening.
- •A positive Hepatitis B surface antigen or Hepatitis C test result at screening
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive Human chorionic gonadotropin (HCG) laboratory test.
- •WOCBP, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 13 weeks after stopping medication.
- •Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
Total Inflammatory Facial Lesion Count at Day 85
时间窗: Day 85
Total inflammatory facial lesion count was the total count of papules, pustules and nodules assessed at day 85
次要结局
- Pharmacokinetics (PK): Serum Trough Concentrations of CJM112 in Period 2(Day 85, Day 113, Day 141 and Day 169)
- Number of Patients With Clinically Significant Abnormal Clinical Chemistry Laboratory Parameters Parameters(38 Weeks)
- Number of Patients With Clinically Significant Abnormal Hematology Laboratory Parameters(38 Weeks)
- Number and Severity of Adverse Events in Period 2(Day 86 to Day 260)
- Pharmacokinetics (PK): Serum Trough Concentrations of CJM112 in Period 1(Day 1, Day 29, Day 57 and Day 85)
- Number and Severity of Adverse Events in Period 1(Day 1 to Day 85)
- Number of Patients With Clinically Significant Abnormal Urinalysis Laboratory Parameters(38 Weeks)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
2 期
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With NarcolepsyNarcolepsyNCT00424931Alza Corporation, DE, USA16
终止
2 期
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the PlaceboMild to Moderate COVID-19NCT04521296Daewoong Pharmaceutical Co. LTD.432
已完成
3 期
Safety and Efficacy Study of YZJ-1139 in Insomnia DisorderInsomnia DisorderNCT05525637Shanghai Haiyan Pharmaceutical Technology Co., Ltd.1,037
已完成
2 期
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's DiseaseCrohn DiseaseNCT02877134Janssen Research & Development, LLC388
已完成
1 期
Monoclonal Antibody Treatment of Crohn's DiseaseCrohn's DiseaseNCT00007163National Institute of Allergy and Infectious Diseases (NIAID)40